A Patient With Recurrent MI: The Role of Antiplatelet Therapies in the Acute and Chronic Stages Following STEMI CME

Author Information and Disclosures

Release Date: April 30, 2008; Valid for credit through April 30, 2009

Credits Available
Physicians - maximum of 1.5 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.
Daiichi-Sankyo, Lilly
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Describe the pathophysiology of acute coronary syndromes as it relates to vulnerable plaque rupture, and platelet adhesion, activation, and aggregation
  2. Apply updated ACC/AHA guidelines for the acute and long-term management of STEMI
  3. Describe the role of dual-antiplatelet therapy in the STEMI patient, including optimal dosing and maintenance therapy
  4. Identify current limitations and variability in patient response to clopidogrel and its effect on outcomes
  5. Review clinical trial data on the use of novel antiplatelet agents
Authors and Disclosures

Stephen D. Wiviott, MD
Disclosure: Stephen D. Wiviott, MD, has disclosed that he has received grants for clinical research from Eli Lilly, Daiichi Sankyo, and Schering Plough. Dr. Wiviott has also disclosed that he has served as an advisor or consultant for Arena, Portola, and sanofi-aventis, and that he has received CME honoraria from Eli Lilly, Daiichi Sankyo, Accumetrics, Astra-Zeneca, Merck, and Pfizer.


Luis Gruberg, MD, FACC
Disclosure: Luis Gruberg, MD, FACC, has disclosed no relevant financial relationships.


David Good
Disclosure: David Good has disclosed no relevant financial relationships.


Ariana Del Negro
Disclosure: Ariana Del Negro has disclosed no relevant financial relationships.


Edward K. Baldwin, PhD
Disclosure: Edward K. Baldwin, PhD, has disclosed that he owns stock, stock options, or bonds in Eli Lilly.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.